VKH
ITCI

Virtu KCG Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Virtu KCG Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,368
Closed -$458K – 3845
2016
Q4 		$458K Buy
30,368
+19,312
+175% +$273K 0.01% 1601
2016
Q3 		$168K Buy
+11,056
New +$447K ﹤0.01% 2454

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Virtu KCG Holdings's ITCI Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2017, closing a stake of 30,368 shares — an estimated $458K sold.

Virtu KCG Holdings first reported a position in ITCI in Q3 2016 and held it in 2 quarters. The position peaked at $458K in Q4 2016. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 30,368 Intra-Cellular Therapies Inc. shares in Q1 2017, an estimated $458K.
  • Virtu KCG Holdings first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Intra-Cellular Therapies Inc. position peaked at $458K in Q4 2016.
  • 117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.